SLC5A7 and Alzheimer disease: Generally, choline uptake activity or binding of the CHT inhibitor hemicholinium-3 (HC-3) is found to be decreased in AD, or in mouse models of AD or neurons treated with β-amyloid peptides (Aβ) [7–11], although some studies have reported little or no changes in these measures [12–14].